Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study

Abstract Background This study focused on comparing the safety and therapeutic effects between icotinib monotherapy and icotinib plus bevacizumab combined therapy in non‐small cell lung cancer (NSCLC) cases harboring EGFR mutations. Methods Data were collected retrospectively from the Cancer Institu...

Full description

Bibliographic Details
Main Authors: Zhansheng Jiang, Jing Zhang, Haiyan Sun, Cong Wang, Yu Zhang, Yanyang Li, Zhanyu Pan
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Thoracic Cancer
Subjects:
bevacizumab
combination therapy
epidermal growth factor receptor (EGFR)
icotinib
non‐small cell lung cancer (NSCLC)
Online Access:https://doi.org/10.1111/1759-7714.14079

Internet

https://doi.org/10.1111/1759-7714.14079

Similar Items